Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Early Phase 1
1(33.3%)
3Total
Phase 1(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05868226Phase 1Recruiting

PRE-ISPY Phase I/II Oncology Platform Program

Role: collaborator

NCT06260774Phase 1Active Not Recruiting

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Role: lead

NCT05908773Early Phase 1Completed

A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors

Role: lead

All 3 trials loaded